From the Analyst's Couch | Published:

Trends in the global immuno-oncology landscape

Nature Reviews Drug Discovery volume 17, pages 783784 (2018) | Download Citation

  • An Erratum to this article was published on 26 October 2018

This article has been updated

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 26 October 2018

    In the original version of Figure 1, the label on the y axis 'T cell-targeted' was incorrect and should be 'T cell-targeted immunomodulator'. The article has been corrected in the online version.

Author information

Affiliations

  1. Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA.

    • Jun Tang
    • , Laura Pearce
    • , Jill O'Donnell-Tormey
    •  & Vanessa M. Hubbard-Lucey

Authors

  1. Search for Jun Tang in:

  2. Search for Laura Pearce in:

  3. Search for Jill O'Donnell-Tormey in:

  4. Search for Vanessa M. Hubbard-Lucey in:

Competing interests

J.O-T. is a paid board member of HemaCare. L. P. is a consultant to Cancer Research Institute and Canadian Cancer Trials Group.

Corresponding author

Correspondence to Jun Tang.

Supplementary information

Excel files

  1. 1.

    Supplementary information

    Supplementary Table

PDF files

  1. 1.

    Supplementary information

    Trends of TAA-targeted IO agents in the past year.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2018.167

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing